Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-13 pm EST			5-day change	1st Jan Change
243.45 ^USD	-0.45%		+1.44%	+17.64%

Feb. 13	Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial	RE
Feb. 13	Pennsylvania jury finds Johnson & Johnson liable for woman's ovarian cancer - attorney for national talc plaintiffs	RE

Health Care Up Amid Deal Speculation -- Health Care Roundup

Published on 01/09/2026 at 05:49 pm EST

Dow Jones

JOHNSON & JOHNSON

-0.45%

ABBVIE INC.

+1.76%

NOVO NORDISK A/S

+1.32%

REVOLUTION MEDICINES, INC.

-1.05%

Health-care companies rose amid deal intrigue.

Merck has entered talks to acquire Revolution Medicines in a deal that could value it at around $30 billion. Biopharmaceutical company AbbVie had previously denied it had entered talks to buy the cancer-drug biotech.

Danish obesity-drug maker Novo Nordisk rose after Amazon Pharmacy began offering pill versions of its GLP-1 drug Wegovy.

Health-care conglomerate Johnson & Johnson agreed to lower the prices of medicines that certain U.S. patients pay, making it the latest pharmaceutical company to strike a pact with the Trump administration.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-09-26 1748ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
JOHNSON & JOHNSON	243.45USD	-0.45%	+1.44%	587B
ABBVIE INC.	231.50USD	+1.76%	+3.61%	409B
NOVO NORDISK A/S	310.60DKK	+1.32%	+5.11%	219B
REVOLUTION MEDICINES, INC.	96.31USD	-1.05%	-1.21%	18.62B

Latest news about Johnson & Johnson

Feb. 13	Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial	RE
Feb. 13	Pennsylvania jury finds Johnson & Johnson liable for woman's ovarian cancer - attorney for national talc plaintiffs	RE
Feb. 13	Olympus Corporation Announces Change of Executive Officer, Effective April 1, 2026	CI
Feb. 13	Olympus Corporation Announces CFO Changes, Effective April 1, 2026	CI
Feb. 12	L'Oreal Bullish on Outshining Rivals in Attractive Beauty Market -- Update	DJ
Feb. 12	Cue Biopharma, Inc. Appoints Lucinda Warren as Chief Financial Officer, Effective February 9, 2026	CI
Feb. 12	Oryzon Genomics, S.A. Announces Chief Medical Officer For CNS Programs Changes	CI
Feb. 11	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
Feb. 09	Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna	RE
Feb. 09	NervGen Pharma Corp. Appoints Adam Rogers as President, Effective February 9, 2026	CI
Feb. 09	NervGen Pharma Corp. Appoints Adam Rogers as Chief Executive Officer, Effective February 9, 2026	CI
Feb. 09	As AI enters the operating room, reports arise of botched surgeries and misidentified body parts	RE
Feb. 07	Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium	CI
Feb. 06	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI

Chart Johnson & Johnson

Duration

Period

JNJ: Dynamic Chart

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Feb. 23 -

More about the company